openPR Logo
Press release

Biliary Tract Cancer (BTCs) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | RemeGen, EMD Serono, SMTbio, InnoPharmax, Roche, Zymeworks, Bristol-Myers Squibb, Eli Lilly, Ipsen, Redx

01-09-2024 05:10 PM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Biliary Tract Cancer (BTCs) Pipeline Analysis Covering

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Biliary Tract Cancer therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Biliary Tract Cancer (BTCs) Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Biliary Tract Cancer Therapeutics Market.

The report provides a detailed description of the Biliary Tract Cancer drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Biliary Tract Cancer Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Biliary Tract Cancer (BTCs) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Biliary Tract Cancer therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Biliary Tract Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Biliary Tract Cancer drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Biliary Tract Cancer treatment market.

Learn More about the Clinical and Commercial Development Activities in the Biliary Tract Cancer Therapeutics Domain @
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Biliary Tract Cancer (BTCs) Therapeutics Analysis
There are approx. 80+ key companies developing therapies for Biliary Tract Cancer. Currently, SMT bio Co., Ltd. is leading the therapeutics market with its Biliary Tract Cancer drug candidates in the most advanced stage of clinical development.

Biliary Tract Cancer (BTCs) Companies in the Therapeutics Market Include:
Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMTbio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison MediPharma Limited, Array BioPharma, Redx Pharma Plc, and Compass Therapeutics. Notably, Lee's Pharmaceutical Limited, and several others.

Emerging and Marketed Biliary Tract Cancer (BTCs) Therapies Covered in the Report Include:
• MRG 002: Miracogen
• Disitamab vedotin: Yantai Rongchang Pharmaceutical
• Envafolimab: Alphamab Oncology
• DKN-01: Leap Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Biliary Tract Cancer Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Biliary Tract Cancer Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Request for Sample PDF to Understand More About the Biliary Tract Cancer Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Biliary Tract Cancer Current Treatment Patterns
4. Biliary Tract Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Biliary Tract Cancer Late-Stage Products (Phase-III)
7. Biliary Tract Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Biliary Tract Cancer Discontinued Products
13. Biliary Tract Cancer Product Profiles
14. Biliary Tract Cancer Companies
15. Biliary Tract Cancer Drugs
16. Dormant and Discontinued Products
17. Biliary Tract Cancer Unmet Needs
18. Biliary Tract Cancer Future Perspectives
19. Biliary Tract Cancer Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biliary Tract Cancer (BTCs) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | RemeGen, EMD Serono, SMTbio, InnoPharmax, Roche, Zymeworks, Bristol-Myers Squibb, Eli Lilly, Ipsen, Redx here

News-ID: 3347167 • Views:

More Releases from DelveInsight Business Research LLP

Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols Therapeutics LLC, Arriva Pharmaceuticals, Inc., Takeda, Kamada Ltd, and others.
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report • The increase in Alpha-1 Protease Inhibitor Deficiency Market Size
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutiscs, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, Un
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Amyloidosis Market Research Report • The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emerging Drugs | Sol-Gel Technologies, Ltd, Premier Research Group plc, PellePharm Inc., DUSA Pharmaceuticals, Inc., Ascend Biopharmaceuticals Inc., Genentech Inc., Palvella Therapeu
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report • The increase in Basal Cell Nevus Syndrome Market Size
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline ReportMirium Pharmaceuticals, Albireo, Intercept Pharmaceuticals, and others. Promising Biliary Atresia Therapies in the various stages of development include BYLVAY, LIVMARLI, and
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Key Takeaways from the Biliary Atresia Market Research Report • The increase in Biliary Atresia Market Size is a direct consequence of the increasing

All 5 Releases


More Releases for Biliary

Biliary Stents Market 2021 Strategic Assessments -
 “The Biliary Stents Market Research Report” examines the existing as well as sequential performance of the worldwide market. The report also calculates the forthcoming status of Biliary Stents market based on thorough analysis. By providing exploratory techniques such as, qualitative and quantitative analysis the report presents a comprehensive analysis of market progression. The report provides Graphical presentation of information through charts, (graphs, diagrams as well as pictures) and easy understanding
U.S. Biliary Stents Market Rise in biliary disorders cases such as benign biliar …
U.S. Biliary Stents Market is projected to reach $474 million by 2025, growing at a CAGR of 5.2 % from 2018 to 2025. The biliary metal stents garnered major shares of the U.S. biliary stents industry, and are expected to maintain this trend during the forecast period. Biliary stents are tubular devices that are made up of plastic or metal. Endoscopic stenting is the most common treatment for obstruction of the
Metal Biliary Stent Market In United State | Classification of Metal Biliary Ste …
Researchmoz added Most up-to-date research on "Metal Biliary Stent Market In United State | Classification of Metal Biliary Stent | Product Overview and Scope" to its huge collection of research reports. This report studies sales (consumption) of Metal Biliary Stent in USA market, focuses on the top players, with sales, price, revenue and market share for each player, covering B.Braun Melsungen Brainlab GE Healthcare Medtronic Stryker Blue Belt Technologies MAKO Claron Technology Karl Storz Fiagon Medacta International Micromar OrthAlign Scopis Zimmer Olympus Medical Systems Fujinon Corporation Hoya Corporation Given
Global Biliary Stents Market: By Application - Preoperative biliary drainage, Bi …
ResearchMoz presents this most up-to-date research on "Global Biliary Stents Market: By Application - Preoperative biliary drainage, Biliary Obstruction and Jaundice Relief & Biliary strictures treatment". This report studies Biliary Stents in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market,
High Prevalence of Biliary Diseases Across the Globe is Driving the Biliary Sten …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.
Rise in Surgical Procedures of Biliary Diseases is Expected to Boost the Biliary …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.